Galectin Therapeutics (GALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Galectin Therapeutics appears to be a pre-revenue, binary-outcome biotech whose equity value rests almost entirely on pipeline optionality, as the company reported no revenue across all ten quarters through 2026Q2 while cutting quarterly R&D 81% from $11.1M in 2024Q4 to $2.1M in 2026Q2, narrowing the quarterly…
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 16, 2026 | -$0.04+20.0% vs -$0.05 | — vs — |
Q3 2026 Aug 14, 2026 | -$0.14-55.6% vs -$0.09 | — vs — |
Q2 2026 May 15, 2026 | -$0.08-33.3% vs -$0.06 | — vs — |
Q2 2026 Mar 31, 2026 | -$0.08+20.0% vs -$0.10 | — vs $36M |
Galectin Therapeutics (GALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NORCROSS, Ga., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2026.
Galectin Therapeutics will present new clinical findings at American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Denver. These results will be covered in one oral presentation and two posters including a Poster of Distinction.
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.
Benchmark GALT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Galectin Therapeutics Inc. (GALT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.98 | $196.25M | -11.51 | — | — | — | — | |
| $95.80 | $11.36B | 24.20 | 37.55% | 26.93% | 544.26% | — | |
| $0.41 | $109.69M | -2.54 | 47.46% | -22.6% | -169.15% | — | |
| $398.08 | $9.18B | -77.62 | 432.05% | -10.89% | -27.07% | — | |
| $44.89 | $3.21B | -30.85 | — | — | -16.91% | — | |
| $17.05 | $3.8B | -20.89 | 59% | -6.65% | -45.81% | — |
Galectin Therapeutics Inc. (GALT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Galectin Therapeutics Inc. (GALT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 4, 2026·SEC
Jun 23, 2026·SEC
Get notified when GALT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Galectin Therapeutics Inc. (GALT) stock FAQ — growth, dividends, profitability & financials explained
No. Galectin Therapeutics Inc. (GALT) reported a net loss of $23.2M over the trailing twelve months.
Galectin Therapeutics Inc. (GALT) had negative free cash flow of $14.6M over the trailing twelve months.